Skip Navigation

European Heart Journal 1994 15(5):665-671;
Copyright © 1994 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by ACHARYA, D. U.
Right arrow Articles by KINSEY, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by ACHARYA, D. U.
Right arrow Articles by KINSEY, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1994 The European Society of Cardiology

Anti-ischaemic and haemodynamic effects of elgodipine, a potent new generation calcium antagonist, in chronic stable angina

D. U. ACHARYA, R. SENIOR, S. BASU, F. HARRISON*, A. GALIANO{dagger}, A. LAHIRI and CHRISTOPHER KINSEY

Department of Cardiology, Northwick Park Hospital and Clinical Research Centre Harrow, U.K.
*Harrison Clinical Research Munich, Germany
{dagger}IQB, Poligono de Alcobendas Madrid, Spain

Received 28 September 1993; revised 28 December 1993; .

Correspondence; Dr A. Lahiri, MB, BS, MSc, MRCP, FACC, Department of Cardiology, Northwick Park Hospital, Harrow, Middlesex, HA1 3UJ, U.K

Abstract

The effects of oral elgodipine, a new dihydropyridine calcium antagonist on ischaemia and left ventricular function were assessed by a single blind placebo controlled study in 12 patients with chronic stable angina. Graded treadmill exercise and echocardiographyl Doppler were performed before and 90 min after single oral doses of elgodipine of 20 mg, 40 mg and 60 mg, or placebo, given at weekly intervals. Elgodipine significantly increased exercise time by 1.1, 2.0 and 2.4 min, (P<0.001 in each case) and time to onset of angina by 1.1 (P<0.01), 19 (P<0.001) and 2.6 min (P<0.001) with increasing doses of the drug. Angina was abolished in 50% of patients with significant improvement in ST depression at peak exercise (P<0.001) with the 60mg dose. Blood pressure fell significantly at rest and peak exercise with a corresponding significant increase in heart rate. Ejection fraction was increased by 78% (P<0.001) and 8.4% (P<0.001) as was the stroke volume by 9.3 ml (P<0.001) and 12.5 ml (P<0.001) at 40 mg and 60 mg respectively. Peak mitral A to E velocity ratio and total peripheral resistance decreased significantly in a dose related linear trend. Only minor side effects were noted and no patient required withdrawal from the study. The results demonstrate that oral elgodipine is a potent anti-ischaemic agent. An improvement in the echocardiographic parameters of left ventricular systolic and diastolic function was also seen

Key Words: Calcium antagonist • elgodipine • coronary heart disease


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.